Brean Murray initiates coverage on Valeant Pharmaceuticals (NYSE: VRX) with a Sell rating and a price target of $9.

This article: 147 words
-->

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE